Literature DB >> 14501795

Estimating HIV prevalence and the impact of HIV/AIDS on a Ugandan hospital by combining serosurvey data and hospital discharge records.

Massimo Fabiani1, Sandro Accorsi, Robert Aleni, Giuliano Rizzardini, Barbara Nattabi, Antonio Gabrielli, Cyprian Opira, Silvia Declich.   

Abstract

OBJECTIVE: To estimate the disease-specific HIV prevalence in a northern Ugandan hospital and to evaluate the impact of HIV/AIDS on hospital services.
DESIGN: HIV serosurvey and analysis of routinely compiled hospital records.
METHODS: The serosurvey was conducted among all 352 patients admitted to the medical ward of the Lacor Hospital in March 1999 (this ward consists of 3 units: general medicine, tuberculosis, and cancer). The impact on hospital services was estimated using the hospital discharge records for all 3447 patients admitted in 1999, in combination with serosurvey data, and was expressed as the percentage of bed-days attributable to HIV-positive patients.
RESULTS: The overall HIV prevalence was 42.0% (52.6, 44.6, and 13.2% in the general medicine, tuberculosis, and cancer units, respectively). The disease-specific prevalence ranged from 45-65% for patients with tuberculosis, pneumonia, malaria, and enteritis. HIV-positive patients, compared with HIV-negative patients, had a higher in-hospital mortality (14.6 vs. 3.0%) and a lower average length of stay (41.4 vs. 48.9 days). AIDS cases accounted for 5.0% of hospital admissions, 4.1% of bed-days, and 11.5% of deaths. When considering all HIV-positive patients, these accounted for 37.2% of the bed-days.
CONCLUSIONS: Knowledge of disease-specific HIV prevalence and of the patterns of HIV-related diseases is crucial for early case management. The impact of HIV-positive patients on hospital services is quite high, accounting for >1/3 of the bed-days in 1999. Providing a continuum of care through inpatient, outpatient, and outreach home care services probably represents the only means of relieving the pressure on overloaded hospitals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501795     DOI: 10.1097/00126334-200309010-00009

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  6 in total

1.  Linkage to HIV care and survival following inpatient HIV counseling and testing.

Authors:  Rhoda K Wanyenze; Judith A Hahn; Cheryl A Liechty; Kathie Ragland; Allan Ronald; Harriet Mayanja-Kizza; Thomas Coates; Moses R Kamya; David R Bangsberg
Journal:  AIDS Behav       Date:  2011-05

2.  Accuracy of Burkitt lymphoma diagnosis in constrained pathology settings: importance to epidemiology.

Authors:  Martin D Ogwang; Weiqiang Zhao; Leona W Ayers; Sam M Mbulaiteye
Journal:  Arch Pathol Lab Med       Date:  2011-04       Impact factor: 5.534

3.  Acceptability of routine HIV counselling and testing, and HIV seroprevalence in Ugandan hospitals.

Authors:  Rhoda K Wanyenze; Cecilia Nawavvu; Alice S Namale; Bernard Mayanja; Rebecca Bunnell; Betty Abang; Gideon Amanyire; Nelson K Sewankambo; Moses R Kamya
Journal:  Bull World Health Organ       Date:  2008-04       Impact factor: 9.408

4.  Eligibility for HIV/AIDS treatment among adults in a medical emergency setting at an urban hospital in Uganda.

Authors:  Damalie Nakanjako; Daniel J Kyabayinze; Harriet Mayanja-Kizza; Elly Katabira; Moses R Kamya
Journal:  Afr Health Sci       Date:  2007-09       Impact factor: 0.927

Review 5.  Healthy, safe and effective international medical student electives: a systematic review and recommendations for program coordinators.

Authors:  D Ashley Watson; Nicholas Cooling; Ian J Woolley
Journal:  Trop Dis Travel Med Vaccines       Date:  2019-04-03

6.  'I believe that the staff have reduced their closeness to patients': an exploratory study on the impact of HIV/AIDS on staff in four rural hospitals in Uganda.

Authors:  Marjolein Dieleman; Vincent Bwete; Everd Maniple; Mirjam Bakker; Grace Namaganda; John Odaga; Gert Jan van der Wilt
Journal:  BMC Health Serv Res       Date:  2007-12-18       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.